JPH0511788B2 - - Google Patents
Info
- Publication number
- JPH0511788B2 JPH0511788B2 JP60233348A JP23334885A JPH0511788B2 JP H0511788 B2 JPH0511788 B2 JP H0511788B2 JP 60233348 A JP60233348 A JP 60233348A JP 23334885 A JP23334885 A JP 23334885A JP H0511788 B2 JPH0511788 B2 JP H0511788B2
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- antibody
- concentration
- difference
- absorbance
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000427 antigen Substances 0.000 claims description 88
- 102000036639 antigens Human genes 0.000 claims description 88
- 108091007433 antigens Proteins 0.000 claims description 88
- 238000002835 absorbance Methods 0.000 claims description 44
- 239000002245 particle Substances 0.000 claims description 35
- 238000006243 chemical reaction Methods 0.000 claims description 24
- 238000002834 transmittance Methods 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 20
- 230000008859 change Effects 0.000 claims description 9
- 230000003100 immobilizing effect Effects 0.000 claims description 2
- 108010074051 C-Reactive Protein Proteins 0.000 description 45
- 102100032752 C-reactive protein Human genes 0.000 description 45
- 239000012085 test solution Substances 0.000 description 37
- 238000012360 testing method Methods 0.000 description 29
- 239000007788 liquid Substances 0.000 description 26
- 238000005259 measurement Methods 0.000 description 22
- 239000000872 buffer Substances 0.000 description 12
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- 238000000691 measurement method Methods 0.000 description 8
- 239000000376 reactant Substances 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- 230000002776 aggregation Effects 0.000 description 5
- 238000004220 aggregation Methods 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 238000007796 conventional method Methods 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 229940027941 immunoglobulin g Drugs 0.000 description 5
- 239000004816 latex Substances 0.000 description 5
- 229920000126 latex Polymers 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000001179 sorption measurement Methods 0.000 description 5
- 238000011546 CRP measurement Methods 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 3
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 3
- 102000013529 alpha-Fetoproteins Human genes 0.000 description 3
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 3
- 239000002612 dispersion medium Substances 0.000 description 3
- 229920000620 organic polymer Polymers 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 229920003048 styrene butadiene rubber Polymers 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 229910052809 inorganic oxide Inorganic materials 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 238000005375 photometry Methods 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 230000005653 Brownian motion process Effects 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 1
- 108010023197 Streptokinase Proteins 0.000 description 1
- 241000589884 Treponema pallidum Species 0.000 description 1
- 238000011481 absorbance measurement Methods 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 229940046836 anti-estrogen Drugs 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 230000003460 anti-nuclear Effects 0.000 description 1
- -1 antinuclear factor Proteins 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 238000005537 brownian motion Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000001268 chyle Anatomy 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000007720 emulsion polymerization reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000000951 immunodiffusion Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940099472 immunoglobulin a Drugs 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000010954 inorganic particle Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Substances N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 1
- 229940117841 methacrylic acid copolymer Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920002454 poly(glycidyl methacrylate) polymer Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000011164 primary particle Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229910000077 silane Inorganic materials 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- CIJQGPVMMRXSQW-UHFFFAOYSA-M sodium;2-aminoacetic acid;hydroxide Chemical compound O.[Na+].NCC([O-])=O CIJQGPVMMRXSQW-UHFFFAOYSA-M 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005202 streptokinase Drugs 0.000 description 1
- 108010075210 streptolysin O Proteins 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
Landscapes
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP23334885A JPS6293664A (ja) | 1985-10-21 | 1985-10-21 | 抗原又は抗体濃度の測定方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP23334885A JPS6293664A (ja) | 1985-10-21 | 1985-10-21 | 抗原又は抗体濃度の測定方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS6293664A JPS6293664A (ja) | 1987-04-30 |
| JPH0511788B2 true JPH0511788B2 (de) | 1993-02-16 |
Family
ID=16953738
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP23334885A Granted JPS6293664A (ja) | 1985-10-21 | 1985-10-21 | 抗原又は抗体濃度の測定方法 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS6293664A (de) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU5407994A (en) * | 1992-10-30 | 1994-05-24 | Cetac Technologies Incorporated | Method for particulate reagent sample treatment |
| JP5312834B2 (ja) * | 2008-03-31 | 2013-10-09 | シスメックス株式会社 | 血液凝固分析装置、血液凝固分析方法、及び、コンピュータプログラム |
| WO2009122993A1 (ja) | 2008-03-31 | 2009-10-08 | シスメックス株式会社 | 血液凝固分析装置、血液凝固分析方法、及びコンピュータプログラム |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS59171863A (ja) * | 1983-03-18 | 1984-09-28 | Mitsubishi Chem Ind Ltd | 抗原抗体反応の測定方法 |
-
1985
- 1985-10-21 JP JP23334885A patent/JPS6293664A/ja active Granted
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS59171863A (ja) * | 1983-03-18 | 1984-09-28 | Mitsubishi Chem Ind Ltd | 抗原抗体反応の測定方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS6293664A (ja) | 1987-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPS6243138B2 (de) | ||
| EP0724156A1 (de) | Satz zum immunologischen Test einer biologischen Substanz und Testprozess | |
| CA2023803C (en) | Method for measuring an immunologically active material and apparatus suitable for practicing said method | |
| AU2002313319B2 (en) | Carrier particle latex for assay reagent and assay reagent | |
| EP0263731A1 (de) | Verfahren zur Messung von Antigen-Antikörper-Reaktionen | |
| JP4086266B2 (ja) | 免疫測定方法 | |
| JPH0511788B2 (de) | ||
| JP3005400B2 (ja) | 抗原または抗体濃度の測定方法 | |
| JPS6293663A (ja) | 抗原又は抗体濃度の測定方法 | |
| JP2004325414A (ja) | 免疫測定方法及び免疫測定キット | |
| EP0439611B1 (de) | Verfahren zum testen einer immunologisch aktiven substanz und dafür geeignetes reagenz | |
| CN111239403B (zh) | 一种β2微球蛋白胶乳增强免疫比浊试剂盒及应用 | |
| JP2001074742A (ja) | ラテックス免疫比濁法および測定キット | |
| JPH0614049B2 (ja) | 抗原又は抗体濃度の測定方法 | |
| JPH06230010A (ja) | 免疫凝集反応試薬及び免疫分析方法 | |
| JPH03233358A (ja) | 抗原または抗体の高感度測定法 | |
| JP3328053B2 (ja) | 免疫凝集反応による抗体又は抗原の濃度定量法 | |
| JPH0682128B2 (ja) | ラテツクス試薬 | |
| JP2575148B2 (ja) | 試 薬 | |
| JP2001050963A (ja) | 免疫学的凝集反応試薬 | |
| JP2704760B2 (ja) | 凝集抗体 | |
| JP2004117068A (ja) | 免疫測定試薬および免疫測定方法 | |
| JPH07111434B2 (ja) | 抗体又は抗原を固定化した不溶性担体粒子の製造方法 | |
| JPH0862214A (ja) | 生体内物質の測定方法 | |
| JPH0814581B2 (ja) | 抗原又は抗体の定量法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| LAPS | Cancellation because of no payment of annual fees |